These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 33020246)

  • 1. Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab.
    Lin JS; Wang DY; Mamlouk O; Glass WF; Abdelrahim M; Yee C; Abudayyeh A
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma.
    Ratanasrimetha P; Reddy VD; Kala J; Tchakarov A; Glass WF; Msaouel P; Lin JS
    Front Immunol; 2022; 13():898811. PubMed ID: 35967405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case Report: THSD7A-Positive Membranous Nephropathy Caused by Tislelizumab in a Lung Cancer Patient.
    Chen M; Zhang L; Zhong W; Zheng K; Ye W; Wang M
    Front Immunol; 2021; 12():619147. PubMed ID: 34040602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint inhibitor-related renal vasculitis and use of rituximab.
    Mamlouk O; Lin JS; Abdelrahim M; Tchakarov AS; Glass WF; Selamet U; Buni M; Abdel-Wahab N; Abudayyeh A
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32718987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IgA nephropathy after pembrolizumab therapy for mesothelioma.
    Wang R; Das T; Takou A
    BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33257374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis.
    Lu W; Gong S; Li J; Luo H; Wang Y
    Medicine (Baltimore); 2020 Apr; 99(16):e19804. PubMed ID: 32311997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature.
    Roccatello D; Sciascia S; Di Simone D; Solfietti L; Naretto C; Fenoglio R; Baldovino S; Menegatti E
    Autoimmun Rev; 2016 Jun; 15(6):529-38. PubMed ID: 26876383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review.
    Abdel-Wahab N; Shah M; Lopez-Olivo MA; Suarez-Almazor ME
    Ann Intern Med; 2018 Jan; 168(2):121-130. PubMed ID: 29297009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study.
    Espi M; Teuma C; Novel-Catin E; Maillet D; Souquet PJ; Dalle S; Koppe L; Fouque D
    Eur J Cancer; 2021 Apr; 147():29-39. PubMed ID: 33607383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles.
    Ye W; Olsson-Brown A; Watson RA; Cheung VTF; Morgan RD; Nassiri I; Cooper R; Taylor CA; Akbani U; Brain O; Matin RN; Coupe N; Middleton MR; Coles M; Sacco JJ; Payne MJ; Fairfax BP
    Br J Cancer; 2021 May; 124(10):1661-1669. PubMed ID: 33723392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).
    Fervenza FC; Canetta PA; Barbour SJ; Lafayette RA; Rovin BH; Aslam N; Hladunewich MA; Irazabal MV; Sethi S; Gipson DS; Reich HN; Brenchley P; Kretzler M; Radhakrishnan J; Hebert LA; Gipson PE; Thomas LF; McCarthy ET; Appel GB; Jefferson JA; Eirin A; Lieske JC; Hogan MC; Greene EL; Dillon JJ; Leung N; Sedor JR; Rizk DV; Blumenthal SS; Lasic LB; Juncos LA; Green DF; Simon J; Sussman AN; Philibert D; Cattran DC;
    Nephron; 2015; 130(3):159-68. PubMed ID: 26087670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.
    Kawsar A; Edwards C; Patel P; Heywood RM; Gupta A; Mann J; Harland C; Heelan K; Larkin J; Lorigan P; Harwood CA; Matin RN; Fearfield L
    Br J Dermatol; 2022 Dec; 187(6):981-987. PubMed ID: 35976170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of long-term repeated rituximab treatment in refractory phospholipase A2 receptor-antibody-related membranous nephropathy.
    Zhang L; Chen M; Le W; Zhang M; Tu Y; Zuo K; Chen D; Wu Y; Li S; Zeng C; Cheng Z; Xie H
    Immunotherapy; 2022 Oct; 14(15):1237-1244. PubMed ID: 36097696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Membranous Nephropathy: It Is Time to Go Back to the Future.
    Sabiu G; Podestà MA
    Nephron; 2021; 145(6):721-727. PubMed ID: 34225270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy.
    Teisseyre M; Cremoni M; Boyer-Suavet S; Ruetsch C; Graça D; Esnault VLM; Brglez V; Seitz-Polski B
    Front Immunol; 2022; 13():859419. PubMed ID: 35603210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
    Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy.
    Moroni G; Depetri F; Del Vecchio L; Gallelli B; Raffiotta F; Giglio E; Brunini F; D'Amico M; Longhi S; Radice A; Messa P; Sinico RA
    Nephrol Dial Transplant; 2017 Oct; 32(10):1691-1696. PubMed ID: 27387472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal Vasculitis and Pauci-immune Glomerulonephritis Associated With Immune Checkpoint Inhibitors.
    Gallan AJ; Alexander E; Reid P; Kutuby F; Chang A; Henriksen KJ
    Am J Kidney Dis; 2019 Dec; 74(6):853-856. PubMed ID: 31204194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
    Weinmann SC; Pisetsky DS
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of primary membranous nephropathy: where are we now?
    Angioi A; Lepori N; López AC; Sethi S; Fervenza FC; Pani A
    J Nephrol; 2018 Aug; 31(4):489-502. PubMed ID: 28875476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.